Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (3667)	12/2/2002 10:18:49 AM
From: William Partmann	Respond to of 10345

I suppose it depends on how they defined major benefit or if they were addressing the antegren trials at all. Bill

To: fred hayes who wrote (3667)	12/2/2002 11:16:15 AM
From: nigel bates	Respond to of 10345

The review paper addresses the issues better than I am likely to. You can download it at - rcpe.ac.uk I'm not arguing whether the conclusions are correct or otherwise, but it seems worth considering.

To: fred hayes who wrote (3667)	12/2/2002 11:24:07 AM
From: fred hayes	Read Replies (1) \| Respond to of 10345

Bill, Nigel, Rick: Nigel's ref looks VERY important. Anxious to hear from whoever can put more perspective on this. The pdf file in Nigel's link challenges the entire basis of current MS treatment, including Avonex. I'm bracing for a major hit on BGEN today. Hoping that Antegren may be outside the scope of the challenge this paper is making... fred